BioPorto yesterday announced that a new CEO for its US business is appointed who will be responsible for the commercialization process in US of the company’s FDA approved NGAL-test, ProNephro AKI. Following the announcement, BioPorto today released its 1. quarter report, showing high growth in its NGAL Test for research use only in the US and had management maintain their guidance for 2024. Later, CEO Peter Mørch Eriksen participated in an event with HCA Capital where the CEO presented the report and reiterated high confidence in BioPorto’s ability to successfully commercialize ProNephro AKI as salespeople from BioPorto and test-equipment maker and partner Roche will begin their marketing efforts of ProNephro AKI in the US in the coming quarters. You can view the event here: https://www.inderes.dk/videos/bioporto-praesentation-af-q1-2024 Disclaimer: HC Andersen Capital receives payment from BioPorto for a DigitalIR/Corporate visibility subscription agreement./ Henrik Ekman 13:45 08.05.2024

info@inderes.fi (inderes.fi)

© Inderes Oyj. All rights reserved.